Upstream Bio (NASDAQ:UPB) Rating Lowered to Neutral at JPMorgan Chase & Co.

Upstream Bio (NASDAQ:UPB) was downgraded by stock analysts at JPMorgan Chase & Co. from an “overweight” rating to a “neutral” rating in a report issued on Friday, Marketbeat Ratings reports. They currently have a $8.00 price target on the stock. JPMorgan Chase & Co.‘s target price indicates a potential upside of 25.39% from the stock’s current price.

UPB has been the subject of several other reports. Mizuho cut their price target on shares of Upstream Bio from $51.00 to $50.00 and set an “outperform” rating for the company in a report on Thursday, May 14th. Weiss Ratings downgraded shares of Upstream Bio from a “sell (d-)” rating to a “sell (e+)” rating in a report on Wednesday, May 6th. Wall Street Zen downgraded shares of Upstream Bio from a “hold” rating to a “sell” rating in a report on Saturday, March 28th. Evercore downgraded shares of Upstream Bio from an “outperform” rating to an “in-line” rating and set a $15.00 price target for the company. in a report on Friday, March 27th. Finally, HC Wainwright started coverage on shares of Upstream Bio in a research report on Wednesday, June 3rd. They issued a “buy” rating and a $36.00 price objective for the company. Four investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $33.17.

Upstream Bio Stock Up 1.6%

Shares of UPB stock opened at $6.38 on Friday. Upstream Bio has a 12-month low of $6.11 and a 12-month high of $33.68. The company has a market capitalization of $347.20 million, a P/E ratio of -2.19 and a beta of 1.10. The firm has a 50-day moving average price of $8.84 and a 200 day moving average price of $16.91.

Upstream Bio (NASDAQ:UPB) last announced its quarterly earnings results on Wednesday, May 13th. The company reported ($0.75) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.73) by ($0.02). Upstream Bio had a negative net margin of 4,718.96% and a negative return on equity of 43.82%. The firm had revenue of $1.03 million for the quarter, compared to the consensus estimate of $1.03 million. As a group, research analysts expect that Upstream Bio will post -2.99 earnings per share for the current year.

Institutional Investors Weigh In On Upstream Bio

Several hedge funds and other institutional investors have recently added to or reduced their stakes in UPB. Norges Bank acquired a new stake in Upstream Bio in the 4th quarter valued at about $78,264,000. UBS Group AG increased its position in Upstream Bio by 563.4% in the 4th quarter. UBS Group AG now owns 1,806,243 shares of the company’s stock valued at $49,039,000 after acquiring an additional 1,533,972 shares in the last quarter. Janus Henderson Group PLC acquired a new stake in Upstream Bio in the 4th quarter valued at about $41,423,000. Y Intercept Hong Kong Ltd increased its position in Upstream Bio by 2,049.2% in the 1st quarter. Y Intercept Hong Kong Ltd now owns 1,000,631 shares of the company’s stock valued at $9,006,000 after acquiring an additional 954,072 shares in the last quarter. Finally, SEB Asset Management AB acquired a new stake in Upstream Bio in the 1st quarter valued at about $7,906,000.

About Upstream Bio

Upstream Bio, Inc is a clinical-stage biotechnology company focused on the development of next-generation prophylactic vaccines and immuno-oncology therapies. Leveraging a proprietary viral vector platform, the company aims to deliver optimized antigen payloads that stimulate robust and durable immune responses against both infectious diseases and cancer targets. Upstream Bio’s approach emphasizes safety, manufacturability and potential for rapid scale-up to address emerging public health challenges.

The company’s research and development pipeline includes multiple viral vector-based candidates in early clinical and preclinical stages.